Abstract
Objectives
To investigate the long-term cost-effectiveness (measured as the ratio of incremental NHS cost to incremental quality-adjusted life years) of a telehealth intervention for patients with raised cardiovascular disease (CVD) risk.
Design
A cohort simulation model developed as part of the economic evaluation conducted alongside the Healthlines randomised controlled trial.
Setting
Patients recruited through primary care, and intervention delivered via telehealth service.
Participants
Participants with a 10-year CVD risk ≥20%, as measured by the QRISK2 algorithm, and with at least 1 modifiable risk factor, individually randomised from 42 general practices in England.
Intervention
A telehealth service delivered over a 12-month period. The intervention involved a series of responsive, theory-led encounters between patients and trained health information advisors who provided access to information resources and supported medication adherence and coordination of care.
Primary and secondary outcome measures
Cost-effectiveness measured by net monetary benefit over the simulated lifetime of trial participants from a UK National Health Service perspective.
Results
The probability that the intervention was cost-effective depended on the duration of the effect of the intervention. The intervention was cost-effective with high probability if effects persisted over the lifetime of intervention recipients. The probability of cost-effectiveness was lower for shorter durations of effect.
Conclusions
The intervention was likely to be cost-effective under a lifetime perspective.
To investigate the long-term cost-effectiveness (measured as the ratio of incremental NHS cost to incremental quality-adjusted life years) of a telehealth intervention for patients with raised cardiovascular disease (CVD) risk.
Design
A cohort simulation model developed as part of the economic evaluation conducted alongside the Healthlines randomised controlled trial.
Setting
Patients recruited through primary care, and intervention delivered via telehealth service.
Participants
Participants with a 10-year CVD risk ≥20%, as measured by the QRISK2 algorithm, and with at least 1 modifiable risk factor, individually randomised from 42 general practices in England.
Intervention
A telehealth service delivered over a 12-month period. The intervention involved a series of responsive, theory-led encounters between patients and trained health information advisors who provided access to information resources and supported medication adherence and coordination of care.
Primary and secondary outcome measures
Cost-effectiveness measured by net monetary benefit over the simulated lifetime of trial participants from a UK National Health Service perspective.
Results
The probability that the intervention was cost-effective depended on the duration of the effect of the intervention. The intervention was cost-effective with high probability if effects persisted over the lifetime of intervention recipients. The probability of cost-effectiveness was lower for shorter durations of effect.
Conclusions
The intervention was likely to be cost-effective under a lifetime perspective.
| Original language | English |
|---|---|
| Article number | e012355 |
| Number of pages | 9 |
| Journal | BMJ Open |
| Volume | 6 |
| Issue number | 9 |
| Early online date | 26 Aug 2016 |
| DOIs | |
| Publication status | Published - Sep 2016 |
Structured keywords
- BTC (Bristol Trials Centre)
- BRTC
Fingerprint Dive into the research topics of 'Cost-effectiveness modelling of telehealth for patients with raised cardiovascular disease risk: evidence from a cohort simulation conducted alongside the Healthlines randomised controlled trial'. Together they form a unique fingerprint.
Profiles
-
Professor Chris Salisbury
- Bristol Medical School (PHS) - Professor in Primary Health Care
- Bristol Population Health Science Institute
- Centre for Academic Primary Care - Professor of Primary Health Care
Person: Academic , Member